Differential effects of acute and chronic antagonist and an irreversible antagonist treatment on cocaine self-administration behavior in rats

Hanna N. Wetzel1,2, Vladimir L. Tsibulsky2 & Andrew B. Norman1*

According to pharmacological theory, the magnitude of an agonist-induced response is related to the number of receptors occupied. If there is a receptor reserve, when the number of receptors is altered the fractional occupancy required to maintain this set number of receptors will change. Therefore, any change in dopamine receptor number will result in a change in the concentration of cocaine required to induce the satiety response. Rats that self-administered cocaine were treated with the irreversible monoamine receptor antagonist, EEDQ, or were infused continuously for 14 days with the D1-like antagonist, SCH23390, treatments known to decrease or increase, respectively, the number of dopamine receptors with a concomitant decrease or increase in response to dopaminergic agonists. The rate of cocaine maintained self-administration increased or decreased in rats treated with EEDQ or withdrawn from chronic SCH23390 infusion, respectively. After EEDQ treatment, the effect ratio of a single dose of SCH23390 or eticlopride were unchanged, indicating that the same SCH23390- and eticlopride-sensitive receptor populations (presumably dopamine) mediated the accelerated cocaine self-administration. Changing the receptor reserve is a key determinate of the rate of cocaine self-administration because the resulting increased or decreased concentration of cocaine results in an accelerated or decelerated rate of cocaine elimination as dictated by first-order kinetics.

Abbreviations

DU  Cocaine unit dose
DST  Satiety threshold
EEDQ  N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline
FR1  Fixed-ratio 1 schedule of cocaine delivery
k  First-order cocaine elimination rate constant
PK/PD  Pharmacokinetic/pharmacodynamic interaction
T  Inter-injection interval

Despite decades of research that have identified dopaminergic neurotransmission as a primary mediator of the actions of cocaine1,2, clinical trials of numerous competitive dopamine receptor antagonists have all failed to provide sufficient evidence of clinical efficacy for the treatment of cocaine use disorders3,4. All of these clinical trials used standard antagonist dosing regimens that were designed to achieve a quasi-steady state for several weeks. In animal studies, such long-term treatments typically result in supersensitive dopaminergic neurotransmission characterized by an increase in the behavioral response to direct and indirect dopamine receptor agonists and a concomitant increase in the number of dopamine receptors5.

Drug self-administration by animals is a commonly used model of human substance use disorder. Maintained self-administration of the indirect dopamine agonist cocaine can be explained by a pharmacokinetic/pharmacodynamic (PK/PD) model where the time between successive self-administrations is determined by the time for the cocaine concentration to decline back to the satiety threshold6. The satiety threshold is defined as the maximal

1Department of Pharmacology and Systems Physiology, University of Cincinnati, College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA. 2Present address: Department of Biology, Xavier University, 3800 Victory Parkway, Cincinnati, OH 45207, USA. *email: andrew.norman@uc.edu
assumed that the animal could not be safely primed and the session was terminated. If the animal was primed, self-administration had been reinstated. If the calculated cocaine concentrations reached 10.0 μmol/kg it was for 30 min. This was done to eliminate the interference of cue-induced lever pressing with the measurement illuminated after every active lever press and at variable intervals of 100–600 s until no lever presses occurred through Saturday). First, rats were placed in the chamber, and a cue-light associated with cocaine injection was used to prevent infection following surgery. Detailed protocols for cocaine self-administration throughout the study. Bupranex (0.03 mg/rat s.c.) was administered for pain relief and gentamycin (25 mg/) of a unit dose of cocaine is caused by a PK/PD interaction where the absolute rate of cocaine elimination is faster at higher concentrations, as dictated by first-order kinetics, so that cocaine levels decline more rapidly to the elevated satiety threshold[13]. Although there is a substantial literature on the acute effects of competitive dopamine receptor antagonists in this model, the effects of protracted treatments with these compounds has been neglected, despite the clear clinical significance. To our knowledge only one study of chronic treatment with a dopamine receptor antagonist on cocaine self-administration has been reported, which studied the selective D1-like competitive antagonist, SCH23390, in non-human primates[14]. It was reported that in some monkeys there were decreases in the rate of responding to a moderate dose of cocaine after the withdrawal from chronic SCH23390 treatment, though the significance of this change was not emphasized. Typically, not all of the receptors in a population need to be occupied by an agonist in order to induce a maximum response, and these represent a receptor reserve. This receptor reserve (sometimes referred to as spare receptors) is the mechanism by which the sensitivity to an agonist is increased by reducing the concentration of agonist required to occupy the necessary number of receptors to induce any defined magnitude of response[15].

Methods
Animals. Male Sprague–Dawley rats between 200 and 500 g during the course of the study were purchased from Harlan Laboratories (Indianapolis, IN). Rats were housed individually on a 14/10-h light/dark cycle with unrestricted access to food and water. All studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and under a protocol approved by the Institutional Animal Care and Use Committee at the University of Cincinnati, and reported in accordance with ARRIVE guidelines.

Self-administration training. Rats were implanted with indwelling catheters into the right jugular vein under isoflurane anesthesia, followed by the left jugular and femoral veins which were catheterized as needed throughout the study. Bupranex (0.03 mg/rat s.c.) was administered for pain relief and gentamycin (25 mg/animal s.c.) was used to prevent infection following surgery. Detailed protocols for cocaine self-administration can be found in Tsibulsky and Norman[15]. In brief, beginning 5 days after surgery, rats were trained to self-administer cocaine HCl. Rats were weighed daily immediately prior to each self-administration session. Animals were placed in isolated chambers containing an active and inactive lever. During training, a unit dose of 3 μmol/kg was delivered on a fixed-ratio 1 (FR1) schedule with a timeout period equal to the time of the injection or 5 s, whichever is longer. A cue-light was illuminated for the duration of timeout. Rats had access to cocaine for 3–4 h a day, 5 days a week. Training was considered complete when inter-injection intervals did not deviate significantly and systematically from the mean for three consecutive sessions.

Self-administration procedures. The self-administration protocol used here was identical to that used previously in this laboratory[15,24]. In short, session began between 8:00 and 10:00 a.m., 6 days a week (Monday through Saturday). First, rats were placed in the chamber, and a cue-light associated with cocaine injection was illuminated after every active lever press and at variable intervals of 100–600 s until no lever presses occurred for 30 min. This was done to eliminate the interference of cue-induced lever pressing with the measurement of cocaine-induced pressing. Once lever-pressing was extinguished, programmed non-contingent injections of cocaine were given every two minutes at escalating doses in order to gradually raise the concentration of cocaine in the rat. When the rat pressed the active lever 5 times with each interval of less than 1 min, it was assumed that self-administration had been reinstated. If the calculated cocaine concentrations reached 10.0 μmol/kg it was assumed that the animal could not be safely primed and the session was terminated. If the animal was primed,
it was allowed to receive 20 injections of a 3 μmol/kg unit dose. After that, the lever was deactivated and animals were left in their chambers until 30 min had passed since their last lever press, at which time animals were returned to their home cages.

Estimations of cocaine level in the body. Cocaine level in the animal was calculated during each self-administration session. Complete protocols for the calculation of cocaine level in the rat’s bodies were found in Tsibulsky and Norman. Briefly, the cocaine level in the body was calculated every second using a one-compartment pharmacokinetic model and assuming 500 s elimination half-life.

The effects of SCH23390 on cocaine self-administration. The baseline values of the inter-injection intervals at 0.3 and 3.0 μmol/kg unit doses were collected for at least 3 weeks prior to the Alzet osmotic pump implantations. Alzet pumps (0.5 μl/h for 14 days, model 2002) were implanted subcutaneously into the back, slightly posterior to the scapulae in the rats under isoflurane anesthesia. These pumps were filled with SCH23390 solutions in saline at three concentrations producing three rates of drug infusion: 26.7 ± 1.7 nmol/kg/h (n = 3), 52.5 ± 3.6 nmol/kg/h (n = 4) and 69.6 ± 2.1 nmol/kg/h (n = 9). For comparison with other published results, the infusion rates were 208, 408 and 541 μg/kg/day, respectively.

Self-administration sessions were conducted on Day 1, 3, and 10 after the pumps were implanted. 14 days after implantation, pumps were extracted under isoflurane anesthesia. Daily self-administration sessions were resumed 1 day after pump extractions and continued for at least 4 weeks.

The effects of EEDQ on cocaine self-administration. Rats were primed using the procedure stated above. After rats had reinstated self-administration, they were allowed to self-administer until stable baseline was established for about 1 h (10–13 self-injections). Immediately following an injection, the rats were removed from the chamber, detached from the syringe, and injected with EEDQ (1 mg/kg in 10% ethanol in saline i.v.) or vehicle (10% ethanol in saline). The animal was immediately reattached to the syringe with cocaine, and put back into the chamber. The rats were allowed to continue self-administration for about 1 h, or if the animal ceased self-administration (determined by no lever-pressing for at least 30 min) they were removed from the chamber and returned to home cages. Self-administration sessions were conducted at 8, 16, 24, 32, 40, 48, 56, 68, 80, 92 and 96 h after injection and then every 24 h until inter-injection intervals returned to baseline. Inter-injection intervals and calculated cocaine levels at the time of lever press during maintenance were recorded during every session.

Determination of the potency of SCH23390 and eticlopride before and after EEDQ treatment. To determine the continued involvement of D1-like and D2-like dopamine receptors in the mediation of satiety threshold following EEDQ treatment, the potencies of SCH23390 (D1-like selective competitive antagonist) and eticlopride (D2-like selective competitive antagonist) were measured. Another group of trained rats were allowed to self-administer until stable baseline was established for about 1 h. Immediately following a cocaine injection, the rat was removed from the chamber and injected with either eticlopride or SCH23390 (each at 20 nmol/kg i.v.) via the same i.v. catheter. Rats were reattached to the cocaine-containing syringe, placed back in the chamber and self-administration resumed. Rats were allowed to continue self-administration for 3–4 h until inter-injection intervals approached baseline. Injections of each antagonist were repeated 3–4 times for each rat, with at least 2 days between sessions.

Following these baseline experiments, the same rats were injected with EEDQ (1 mg/kg). Beginning 4 h after EEDQ injection, attempts to prime the rats were made every 8 h. As soon as self-administration was reinstated, they were allowed to self-administer for approximately 1 h to establish the new stable baseline intervals. Animals were removed from the chamber, detached from the syringe, and injected with either eticlopride or SCH23390 (20 nmol/kg i.v.) as done prior to EEDQ treatment. Rats were reattached to the syringe and placed back in the chambers and allowed to continue self-administration until inter-injection intervals returned to the elevated baseline. On five occasions, competitive antagonist treatment abolished self-administration behavior or the elevated cocaine concentrations induced seizures. In these cases, the antagonist injections were repeated every 24 h until reliable self-administration following treatment was achieved. The ratio of the highest level of cocaine at the time of lever-presses after antagonist injection to the mean baseline levels during the same session in the same rat was calculated. All injections of dopamine antagonists were given within 4 days after EEDQ administration.

Drugs. (−)-Cocaine HCl was provided by the Research Triangle Institute (Chapel Hill, NC) under the National Institute on Drug Abuse drug supply program. EEDQ, SCH23390 HCl and S(−)-Eticlopride HCl were purchased from Sigma-Aldrich, St. Louis, MO. Cocaine was dissolved in saline at the concentration of 40 μmol/ml. EEDQ was dissolved in 95% ethanol at the concentration of 2.0 mg/ml immediately or not more than 3 days before the injection. Stock solution of SCH23390 and Eticlopride were dissolved in 95% ethanol at the concentration of 20 μmol/ml, were stored at −20 °C. Solutions were further diluted before animal injections for a maximum ethanol concentration of 10%. The dose of ethanol injected along with eticlopride or SCH23390 was 0.02 mg/kg and did not affect cocaine self-administration behavior.

Data analysis and statistics. Baseline inter-injection interval values within sessions were typically log-normally distributed. Therefore, all statistical analyses of these two parameters were performed using their logarithmic values. Inter-injection intervals were averaged for each session. Baseline trends were determined for at least 3 weeks prior the vehicle, EEDQ, or SCH23390 injections. Baseline values of mean inter-injection intervals...
were extrapolated for each rat using linear regression analysis. Following treatment, the values of mean inter-injection intervals were compared with respective baseline values expected on the same day using a paired t-test, as previously reported. Nonlinear regression analyses of the recovery of inter-injection intervals and the estimation of treatment effect half-lives were calculated according to a mono-exponential equation in each individual rat.

The effects of competitive dopamine receptor antagonists on inter-injection intervals before and after EEDQ injections were statistically assessed using a paired t-test comparing mean ratios before EEDQ and ratios in the session immediately following EEDQ. Graphic and statistical analyses were conducted using SigmaPlot (Systat Software Inc., San Jose, CA). Multiple comparison correction was performed according to the False Discovery Rate (FDR) method. The significance level was set at \( p = 0.05 \).

**Significance statement.** Irreversible and competitive antagonist treatments that reduce or increase dopamine receptor number in the brain accelerate or decelerate, respectively, cocaine self-administration in rats. While the acute effect of competitive dopamine receptor antagonists is to accelerate self-administration behavior, withdrawal from chronic dopamine receptor antagonist treatment has the opposite effect. Dopamine receptor concentrations vary in a number of situations, including substance use disorders, and as a result of the natural aging process. Changes in receptor numbers in individual humans could influence cocaine use.

**Results**

**Effect of SCH23390 infusion on Inter-Injection Intervals.** Representative cocaine self-administration sessions from the same rat before, during and after a 2-week infusion of SCH23390 are shown in Fig. 1. In all sessions, after self-administration was reinstated by the programmed injections of cocaine there was a brief loading period characterized by very short inter-injection intervals (Fig. 1A). Subsequently, the self-administration of 0.3 µmol/kg of cocaine was characterized by short and regular inter-injection intervals. When the unit dose of cocaine increased tenfold, there was an abrupt increase in inter-injection intervals, and these intervals were also regular. This same pattern was seen in all three sessions. However, after implantation of the Alzet pumps the inter-injection intervals were significantly shorter compared with the baselines at both unit doses. After the
withdrawal of the constant SCH23390 infusion, the inter-injection intervals at each unit dose were considerably longer than those observed before the beginning of the antagonist infusion.

In both sessions, despite the large increase in inter-injection intervals when the unit dose was increased tenfold, there was little change in the calculated cocaine concentrations at the time of each lever press (Fig. 1B). However, after implantation of the Alzet pumps the minimal maintained cocaine level increased significantly at both unit doses. After the withdrawal of the constant SCH23390 infusion, the calculated cocaine level at the time of each lever press at both unit doses were considerably lower than that observed before and during the antagonist infusion.

During the infusion of SCH23390, the mean inter-injection intervals were significantly decreased at both cocaine unit doses (Fig. 2A,B) across the 14 days of infusion. Analyses showed significant effects of treatment on the inter-injection intervals at 0.3 µmol/kg (the one-way ANOVA, F_{1,15} = 136.3, p < 0.001) and at 3.0 µmol/kg unit dose (F_{1,15} = 138.95, p < 0.001). The acceleration of cocaine self-administration was similar to the acute effects of a single dose of SCH23390 [8,26]. After removal of the Alzet pumps the mean inter-injection intervals increased to 49.9 s (increase over the baseline by 49.9% at 0.3 µmol/kg) and to 447.4 s (by 32.6% at 3.0 µmol/kg), then gradually returned to the baseline levels over the next 2 weeks. The one-way ANOVA showed a significant effect of withdrawal on the inter-injection intervals both at 0.3 µmol/kg (the one-way ANOVA, F_{1,17} = 264.8, p < 0.001) and 3.0 µmol/kg (F_{1,17} = 91.86, p < 0.001). The half-life of the recovery rate was in the range between 8 and 14 days (Fig. 2).

The effects of EEDQ on maintenance of self-administration. Due to the lack of difference in the effect on intervals at the 0.3 and 3.0 µmol/kg doses in the previous experiment with chronic SCH23390, only the 3.0 µmol/kg unit dose was used in the following experiments. This shortened the self-administration session, thus minimizing exposure to cocaine while maximizing data collection. After EEDQ exposure rats were able to
maintain stable intervals between cocaine injections (Fig. 3). At the peak of the effect, 24 h after EEDQ injection, inter-injection intervals were 52.8% shorter (the mean 173.3 s, with the SD range of 116.4–258.2 s) than baseline values in all rats (367.0 s, 324.9–414.2 s). The one-way ANOVA showed the significant effect of EEDQ ($F_{1,21} = 108.094, p < 0.001$). Intervals gradually returned to the baseline levels within 7–10 days (Fig. 4A). This recovery process was approximated by the equation for mono-exponential growth to the maximum. The average recovery half-life was $2.9 \pm 0.3$ days.

The effects of a frequent access protocol on self-administration behavior. A group of six animals (three of them were the same rats as in EEDQ group) was injected with a vehicle control, but exposed to the same frequent access self-administration schedule as the EEDQ treated animals. Initially, the frequent access protocol caused a significant decrease in inter-injection intervals. However, this effect was variable between rats (Fig. 4B). The one-way ANOVA showed that the frequent access protocol significantly decreased inter-injection intervals ($F_{1,18} = 16.78, p < 0.001$). The effect reached the peak of $-28.7\%$ on Day 5 after the beginning of the frequent access protocol. The recovery started immediately after the interval between sessions returned to the standard 24 h and was complete in 5 more days. The average recovery half-life was $12.3 \pm 4.6$ days.

The magnitude of response to SCH23390 and eticlopride after EEDQ treatment. Following the injection of the competitive antagonists eticlopride or SCH23390, the inter-injection intervals were shorter (data not shown). This acceleration of cocaine self-administration behavior is consistent with previously published observations.\cite{5,11,13} The rate of self-administration plateaued in approximately 25–30 min for both competitive antagonists, and then gradually returned towards the pre-injection rate. The mean baseline inter-injection intervals for sessions before eticlopride injection was 341.4 ± 20.2 s and the plateau interval was 191.6 ± 8.7 s. The mean baseline inter-injection intervals for sessions before SCH23390 injection was 395.9 ± 17.4 s and the plateau interval was 181.1 ± 9.7 s. In rats administered EEDQ, the competitive antagonists also produced an acceleration of self-administration behavior, in addition to that produced by EEDQ, with the same pattern of a plateau and subsequent return to the pre-injection levels. The time-course of the competitive antagonist effects was similar to that observed in the animals when not treated with EEDQ. The mean pre-eticlopride inter-injection interval was 230.0 ± 21.2 s and the plateau interval was 119.0 ± 8.2 s. The mean pre-SCH23390 inter-injection interval was 291.4 ± 23.5 s and the plateau interval was 127.6 ± 9.8 s. The ratios of the plateau rates compared to pre-injection rates are presented in Table 1. There were no significant differences in these ratios for each competitive antagonist in rats administered EEDQ or not administered EEDQ.
The ratios of the peak satiety threshold to baseline satiety threshold is an indication of the potency of dopamine antagonists. A representative session is shown in Fig. 5. The ratio between baseline and the peak effect was measured before and after EEDQ injection. This was used as an indicator of the antagonist potency when the total number of dopamine receptors had been significantly reduced. EEDQ significantly increased the satiety threshold. Despite a large increase in baseline satiety threshold from 4.6 ± 0.2 μmol/kg to 8.1 ± 0.9 μmol/kg on the first successful priming session after EEDQ injection, there was no significant difference in the ratio of baseline to the peak effect after SCH23390 or eticlopride injection (Table 1).

**Discussion**

**Acute reversible antagonist treatment.** The acceleration of cocaine self-administration after pre-session systemic injections of selective D1 and D2 dopamine receptor antagonists are well established. The acceleration, plateau and subsequent slowing of cocaine self-administration after a single i.v. injection of reversible dopamine receptor antagonists during the maintenance phase of a session were observed in this study.
The cocaine level at the time of lever press during cocaine maintained self-administration represents the satiety threshold and is assumed to be an equiactive agonist concentration. Competitive antagonists increase the equiactive agonist concentration, and the ratio of this concentration before and after antagonist treatment is a measure of antagonist potency. Therefore, the ratio of the cocaine satiety threshold before and after eticlopride or SCH23390 is a measure of their potencies. A dose of antagonist that produces a twofold increase in the equiactive agonist concentration represents the Kdose, which is approximately 20 nmol/kg for both eticlopride and SCH23390.

**Chronic reversible antagonist treatment and withdrawal.** During the continuous infusion of SCH23390, cocaine self-administration was accelerated with a decrease in intervals at a similar magnitude observed after a single injection of SCH23390. This indicates that SCH23390 was actively antagonizing dopamine receptors throughout the infusion.

Withdrawal from chronic treatment with SCH23390 reveals an upregulation of D1-like receptors and produces an increased behavioral response to dopamine receptor agonists. In the present study, the effects of supersensitive dopamine systems are characterized by a marked decrease in the rate of cocaine self-administration on Days 2–7 after discontinuing the chronic antagonist infusion (Fig. 2), which is consistent with the report of the effects of chronic SCH23390 on cocaine self-administration in monkeys. This deceleration of self-administration behavior resulting from a supersensitive system is opposite to the acceleration induced by a single dose of SCH23390. We have previously proposed that the SCH2330-induced acceleration of cocaine self-administration behavior is the result of a PK/PD interaction where an increase in the satiety threshold results in an increase in the rate of elimination of cocaine. Similarly, a supersensitive dopamine system would result in a decrease in the rate of elimination of cocaine.
in a decrease in the cocaine satiety threshold. Consequently, the rate of cocaine elimination would be slower at the lower concentrations, as dictated by first-order kinetics, and it would take longer for cocaine concentrations after injection to fall to the lowered satiety threshold. Figure 6 illustrates this model.

The magnitude of the deceleration of cocaine self-administration behavior was substantial and the effect was measurable for more than a week before returning to baseline. Therefore, the observed effect on cocaine self-administration behavior during and after chronic antagonist treatment is opposite when the antagonist concentration declines and uncovers a supersensitive dopamine system.

The supersensitivity of agonist-induced responses after chronic antagonist treatments is typically assumed to be due to the observed increase in the number of receptors. Indeed, the treatment of rats with adenovirus that carried the D2 receptor gene to upregulate D2 dopamine receptors in the nucleus accumbens resulted in a significant decrease (75%) in cocaine consumption. The duration of this effect corresponded to the time needed for the number of D2 receptors to return to baseline. It is likely that the increase in receptor number results in an increased receptor reserve, which enhances the sensitivity of the system to receptor agonists by reducing the concentration of agonist required to induce a defined magnitude of response.

**Acute irreversible antagonist treatment.** The injection of a single dose of EEDQ resulted in immediate acceleration of cocaine self-administration. This effect remained long after the EEDQ would have cleared from the rat (Fig. 4A), for which the longest estimates are about 24 h, consistent with the irreversible antagonism of the receptors underlying this behavior. If so, the observed acceleration of self-administration behavior was due to the decreased total number of receptors. The time course of recovery of the rate of self-administration behavior is consistent with the rate of recovery of both D1- and D2-like dopamine receptor populations in rat striatum after a single treatment with EEDQ. This implies that the satiety response requires only a relatively low number of dopamine receptors. This indicates that there is a substantial receptor reserve in the systems underlying cocaine maintained self-administration behavior. If the effect of EEDQ is similar to that observed in previous studies, then the satiety response may be observed when only approximately 20% of D1- and D2-like dopamine receptors are present. It is possible that receptor transduction efficiency is also changed after EEDQ treatment, which might account for the rapid reappearance of cocaine self-administration behavior, typically within a day after EEDQ. The observed acceleration of cocaine self-administration after EEDQ treatment is consistent with the report that in mutant mice lacking D2 receptors the rate of cocaine self-administration was accelerated.

In the case of the EEDQ-induced acceleration of cocaine self-administration, the reduction of the number of receptors reduced the receptor reserve, so a higher concentration of agonist is required in order to occupy the fixed number of receptors required to produce a particular magnitude of response. It is a fundamental principle of pharmacology that a set number of receptors that are occupied by an agonist will induce a particular magnitude of response. Therefore, the number of receptors occupied by an agonist at the satiety threshold should also be constant. This number may be constant under any situation, whether there is a normal, a depleted or an
increased receptor population. If so, the mechanistic definition of the satiety threshold would be the minimum number of receptors required to induce the satiety response. In contrast to this mechanistic definition of the satiety threshold, the operational definition of the satiety threshold was based on the minimum dose of cocaine required to produce a cocaine concentration that induced the satiety response.

More frequent access to cocaine. The increase in the rate of cocaine self-administration observed in the control (vehicle treated) rats in the days following the vehicle injection is likely due to the increased exposure to self-administered cocaine. During this time, the sessions were run every 8 h, rather than daily, and the effect is similar to the reported escalation of cocaine intake observed for ten days under a frequent access daily regimen of self-administration. For the first 3 days after injection of either vehicle or EEDQ, the total duration of three self-administration sessions was about 6 h. It has been demonstrated that the single long access session of 6 h also results in significant decrease of inter-injection intervals at a wide range of cocaine unit doses. It is possible that this phenomenon can be explained by the development of tolerance to cocaine with more frequent access. More cocaine would be required to induce the same magnitude of response, and would be consistent with a down regulation of the number of dopamine receptors.

Change in fractional occupancy. If the number of occupied receptors required to induce the satiety response is constant, a change in the total number of receptors results in a change only in the receptor reserve and, therefore, in the fraction of the total receptor population required to induce the satiety response. This fraction is increased by EEDQ because the total number of receptors is decreased, and decreased by chronic SCH23390 because the total number of receptors is increased. Fractional occupancy by a ligand is dependent on a ligand's affinity and concentration. Assuming unchanged affinity, the increased fractional occupancy will require a higher concentration of a ligand. Consequently, if it is assumed that the number of occupied receptors required to induce the satiety response is constant, then fractional occupancy of the remaining receptor population after EEDQ must be increased. At the elevated satiety threshold concentration, the cocaine elimination rate is increased as dictated by first-order elimination kinetics. As a result, the cocaine concentration produced by a unit dose of cocaine decreases more rapidly to the elevated satiety threshold concentration, thereby shortening the inter-injection interval, similar to the effect of a single injection of a competitive antagonist. This explanation is illustrated in Fig. 6.

The response to irreversible antagonism of dopamine receptors was similar to that produced after acute treatment with the competitive D1-like receptor antagonist, SCH23390 (Fig. 2 and Table 1), and the competitive D2-like receptor antagonist eticlopride (Fig. 5). Despite the similar acceleration of self-administration behavior, these two classes of antagonists have distinct mechanisms of action, with only EEDQ changing the number of available receptors. The SCH23390- and eticlopride-induced acceleration of cocaine self-administration was previously explained by an increase in the cocaine concentration required to induce the same magnitude of a quantal response, corresponding to the satiety threshold. Importantly, it is the change in cocaine concentration that results in the change in intervals in the presence of competitive antagonists, EEDQ, or in a supersensitive system.

It has previously been shown that the potencies of competitive dopamine receptor antagonists can be determined using Schild analysis of the increase in satiety threshold as a function of antagonist dose. Since the cocaine concentration ratio for the same dose of SCH23390 or eticlopride was not altered after a treatment with EEDQ it was concluded that the pharmacology of the receptor populations underlying cocaine self-administration were unaltered. Since EEDQ is not selective for subtypes of dopamine receptors, or for several monoamine receptors, the continued involvement of dopamine receptors following this non-selective receptor knock-down was confirmed by the unchanged satiety threshold ratios, and therefore relative potencies, of the selective D1-like (SCH23390) and D2-like (eticlopride) competitive antagonists (Fig. 5, Table 1).

Summary and limitations

There are a few key limitations of this research. First, only male rats were included. The lack of inclusion of female rats is a weakness. Additionally, all experiments were done using an FR1 schedule and animals were primed using non-contingent doses of cocaine. This may limit the translation of this work into humans. Lastly, cocaine levels in the animals were all calculated and not measured.

In summary, treatments that have been shown to produce an increase or a decrease in receptor number result in opposite effects on the rate of cocaine self-administration behavior. At the changed cocaine concentration required to occupy the same number of receptors, the rate of elimination of cocaine is changed according to the law of first-order kinetics. The change in inter-injection interval is a direct consequence of this pharmacokinetic/pharmacodynamic interaction. The role of receptor number (or efficiency/sensitivity) and receptor occupancy play a key role in regulating the rate of cocaine self-administration behavior. These findings could have clinical relevance. Dopamine receptor concentrations vary in a number of situations, including substance use disorders, and as a result of the natural aging process. Changes in receptor numbers in individual humans could influence cocaine use after protracted antagonist treatment.

Received: 6 December 2021; Accepted: 9 May 2022
Published online: 24 May 2022

References
1. Ritz, M. C., Lamb, R. J., Goldberg, S. R. & Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219–1223. https://doi.org/10.1126/science.2820058 (1987).
2. Wise, R. A. Cocaine reward and cocaine craving: The role of dopamine in perspective. NIDA Res. Monogr. 145, 191–206 (1994).
3. Voci, E. & Ling, W. Medications development: Successes and challenges. Pharmacol. Ther. 108, 94–108. https://doi.org/10.1016/j.pharmthera.2005.06.010 (2005).
4. Chan, B. et al. Pharmacotherapy for cocaine use disorder — A systematic review and meta-analysis. J. Gen. Intern. Med. 34, 2858–2873. https://doi.org/10.1007/s11606-019-05074-8 (2019).
5. Creese, I. & Sibley, D. R. Receptor adaptations to centrally acting drugs. Annu. Rev. Pharmacol. Toxicol. 21, 357–391. https://doi.org/10.1146/annurev.pa.21.040181.002041 (1981).
6. Tsibulsky, V. L. & Norman, A. B. Satiety threshold: A quantitative model of maintained cocaine self-administration. Brain Res. 839, 85–93 (1999).
7. Tsibulsky, V. L. & Norman, A. B. Methodological and analytical issues of progressive ratio schedules: Definition and scaling of breakpoint. J. Neurosci. Methods 356, 109146. https://doi.org/10.1016/j.jneumeth.2021.109146 (2021).
8. Koob, G. F., Le, H. T. & Creese, I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci. Lett. 79, 315–320. https://doi.org/10.1016/0304-3940(87)90531-9 (1987).
9. Norman, A. B., Tabet, M. R., Norman, M. K. & Tsibulsky, V. L. Using the self-administration of apomorphine and cocaine to measure the pharmacodynamic potencies and pharmacokinetics of competitive dopamine receptor antagonists. J. Neurosci. Methods 194, 252–258. https://doi.org/10.1016/j.jneumeth.2010.01.017 (2011).
10. Wise, R. A. Dopamine and reward: The anhedonia hypothesis 30 years on. Neurotox. Res. 14, 169–183. https://doi.org/10.1007/BF03033808 (2008).
11. Norman, A. B. et al. The affinity of D2-like dopamine receptor antagonists determines the time to maximal effect on cocaine self-administration. J. Pharmacol. Exp. Ther. 338, 724–728. https://doi.org/10.1124/jpet.111.183244 (2011).
12. Schild, H. O. pAx and competitive drug antagonism. Br. J. Pharmacol. Chemother. 4, 277–280. https://doi.org/10.1111/j.1476-5381.1949.tb00548.x (1949).
13. Norman, A. B., Norman, M. K., Tabet, M. R., Tsibulsky, V. L. & Pesce, A. J. Competitive dopamine receptor antagonists increase the equiactive cocaine concentration during self-administration. Synapse 65, 404–411. https://doi.org/10.1002/syn.20858 (2011).
14. Kleven, M. S. & Woolverton, W. L. Effects of continuous infusions of SCH 23390 on cocaine- or food-maintained behavior in rhesus monkeys. Behav. Pharmacol. 1, 365–373. https://doi.org/10.1097/00008877-199001400-00010 (1990).
15. Kenakin, T. Pharmacologic Analysis of Drug-Receptor Interaction 3rd edn. (Lippincott-Raven Publishers, 1997).
16. Battaglia, G., Norman, A. B. & Creese, I. Age-related differential recovery rates of rat striatal D-1 dopamine receptors following irreversible inactivation. Eur. J. Pharmacol. 145, 281–290. https://doi.org/10.1016/0014-2999(88)90431-1 (1988).
17. Tarazi, F. I., Kula, N. S., Zhang, K. & Baldessarini, R. J. Alkylation of rat dopamine transporters and blockade of dopamine uptake by EEDQ. Neuropharmacology 39, 2133–2138. https://doi.org/10.1006/nuph.2000.0473 (2000).
18. Norman, A. B., Battaglia, G. & Creese, I. Differential recovery rates of D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: A key to receptor regulatory mechanisms. J. Neurosci. 7, 1484–1491 (1987).
19. Porceddu, M. L., Ongini, E. & Biggio, G. [3H]SCH 23390 binding sites increase after chronic blockade of D-1 dopamine receptors. Brain Res. 846, 203–207 (1999).
20. Creese, I. & Chen, A. Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. Eur. J. Pharmacol. 109, 127–128. https://doi.org/10.1016/0014-2999(85)90549-7 (1985).
21. Hess, E. J., Norman, A. B. & Creese, I. Chronic treatment with dopamine receptor antagonists: Behavioral and pharmacologic effects on D1 and D2 dopamine receptors. J. Neurosci. 8, 2361–2370 (1988).
22. Hu, X. T. & White, F. J. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: Electrophysiological and behavioral studies. Synapse 17, 43–61. https://doi.org/10.1002/syn.890170106 (1994).
23. Tsibulsky, V. L. & Norman, A. B. Real time computation of in vivo drug levels during drug self-administration experiments. Brain Res. Brain Res. Protoc. 15, 38–45. https://doi.org/10.1016/j.brainresprot.2005.03.003 (2005).
24. Wetzel, H. N., Tsibulsky, V. L. & Norman, A. B. The effects of a repeated dose of a recombinant humanized anti-cocaine monoclonal antibody on cocaine self-administration in rats. Drug Alcohol Depend. 168, 287–292. https://doi.org/10.1016/j.drugalcdep.2016.09.024 (2016).
25. Curran-Everett, D. Multiple comparisons: Philosophies and illustrations. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1–8. https://doi.org/10.1152/ajpregu.2000.279.1.R1 (2000).
26. Norman, A. B., Belge, J. A. & Tsibulsky, V. L. Characterization of the distribution of the cocaine priming threshold and the effect of SCH23390. Brain Res. 946, 253–261 (2002).
27. Bergman, I., Kamien, J. B. & Spealman, R. D. Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav. Pharmacol. 1, 355–363. https://doi.org/10.1097/00008877-199001400-00009 (1990).
28. Schild, H. O. Drug antagonism and pAx. Pharmacol. Rev. 9, 242–246 (1957).
29. Hess, E. J., Albers, I. J., Le, H. & Creese, I. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: Potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J. Pharmacol. Exp. Ther. 238, 846–854 (1986).
30. Thanos, P. K., Michaelides, M., Umegeki, H. & Volkow, N. D. D2R DNA transfer into the nucleus accumbens attenuates cocaine self-administration in rats. Synapse 62, 481–486. https://doi.org/10.1002/syn.20523 (2008).
31. Nowak, G. Measurement of the receptor turnover using an irreversible inactivating method. Theoretical assumptions, limitations and practical realization. Pol. J. Pharmacol. Pharm. 42, 433–440 (1990).
32. Caine, S. B. et al. Role of dopamine D2-like receptors in cocaine self-administration: Studies with D2 receptor mutant mice and novel D2 receptor antagonists. J. Neurosci. 22, 2977–2988 (2002).
33. Emmett-Oglesby, M. W. et al. Tolerance to self-administration of cocaine in rats: Time course and dose-response determination using a multi-dose method. Drug Alcohol Depend. 32, 247–256. https://doi.org/10.1016/0376-8716(93)90089-9 (1993).
34. Ahmed, S. H. & Koob, G. F. Long-lasting increase in the set point for cocaine self-administration after escalation in rats. Psychopharmacology 146, 303–312. https://doi.org/10.1007/s002130051211 (1999).
35. Karrer, T. M., Josef, A. K., Mata, R., Morris, E. D. & Samanez-Larkin, G. R. Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: A meta-analysis. Neurobiol. Aging 57, 36–46. https://doi.org/10.1016/j.neurobiolaging.2017.05.006 (2017).

Author contributions
All authors participated in the research design and wrote and edited the main manuscript text. V.T. and H.W. conducted the experiments, analyzed data and prepared the figures.

Funding
This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grant DP1DA031386].

Competing interests
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to A.B.N.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022